Tumor Necrosis Factor Receptor Superfamily Member 10b
Introduction
TNFRSF10B (Tumor Necrosis Factor Receptor Superfamily Member 10B), also known as Death Receptor 5 (DR5), is a crucial component of the extrinsic apoptotic pathway, responsible for initiating programmed cell death in response to specific signals. It belongs to the tumor necrosis factor receptor superfamily, a group of cell surface receptors that play vital roles in regulating immunity, inflammation, and cell survival or death.
Biological Basis
The primary function of TNFRSF10B is to bind to its specific ligand, TRAIL (TNF-related apoptosis-inducing ligand). Upon binding, TNFRSF10B recruits adapter proteins, forming a death-inducing signaling complex (DISC) that activates a cascade of cysteine proteases known as caspases. This activation ultimately leads to the dismantling of the cell through apoptosis, a highly regulated process essential for tissue homeostasis, development, and the removal of damaged or unwanted cells. TNFRSF10B is widely expressed in various tissues and its activity is tightly controlled to prevent unintended cell death.
Clinical Relevance
Dysregulation of TNFRSF10B and the TRAIL-DR5 pathway is implicated in a variety of human diseases, most notably cancer. In many cancers, tumor cells can develop resistance to TRAIL-induced apoptosis, allowing them to evade immune surveillance and proliferate unchecked. Conversely, enhancing TNFRSF10B signaling is a strategy explored in cancer therapy, with various agonists and antibodies designed to selectively induce apoptosis in malignant cells. Understanding the genetic variations and expression patterns of TNFRSF10B can provide insights into disease progression, prognosis, and potential therapeutic responses.
Social Importance
The study of TNFRSF10B holds significant social importance, particularly in the realm of medicine and public health. Research into this gene contributes to a deeper understanding of fundamental cellular processes like apoptosis, which is critical for health and disease. For patients, particularly those with cancer, insights into TNFRSF10B can pave the way for more effective and personalized treatment strategies, potentially leading to improved outcomes and reduced side effects. Furthermore, it highlights the complex interplay between genetics, immunity, and disease, fostering a broader appreciation for molecular biology's impact on human well-being.
Methodological and Statistical Constraints
Genetic association studies, particularly early genome-wide association studies (GWAS) and protein quantitative trait loci (pQTL) analyses, often encounter limitations in statistical power and study design. Many investigations, especially those employing family-based association tests or linkage analyses, may lack the power to robustly detect genetic variants that contribute only small effects to complex phenotypes, making it challenging to confidently distinguish true genetic signals from random noise. [1] Furthermore, the comprehensiveness of single nucleotide polymorphism (SNP) coverage in specific genomic regions can be a limiting factor, as insufficient density of markers may lead to missed associations, suggesting that more advanced, higher-density SNP arrays could provide a more complete picture. [2]
Another critical consideration is the rigorous handling of statistical significance in the face of multiple comparisons. Some reported p-values in genetic association studies were initially unadjusted, which necessitates their interpretation against highly stringent corrected thresholds, such as those derived from Bonferroni adjustments. [3] While efforts are made to account for population stratification, some associations, even if nominally significant, may not withstand more conservative validation methods like permutation testing or non-parametric analyses. [4] Moreover, the extensive statistical correction required for genome-wide and phenotype-wide testing, particularly when searching for trans effects across numerous traits, can inadvertently reduce the power to detect genuine, albeit weaker, genetic influences, potentially leading to an underestimation of the full genetic architecture of a trait. [4]
Phenotypic Measurement and Confounding Factors
The accurate and consistent measurement of complex phenotypes, such as circulating protein levels, presents significant challenges that can impact the reliability of genetic associations. For several proteins, including Interleukin-1b, Interleukin-8, and Monocyte Chemoattractant Protein-1, a notable proportion of study participants exhibited levels below the detectable limits of the assays. [4] In such cases, researchers often resort to dichotomizing continuous traits, which can lead to a loss of valuable information and a reduction in statistical power to detect subtle genetic effects. [4] A further concern regarding protein measurements is the potential for identified SNPs to influence antibody binding affinity rather than the actual concentration of the protein, which could lead to misinterpretation of genetic effects and would require extensive re-sequencing to definitively resolve. [4]
Beyond technical measurement issues, phenotypic values can be significantly modulated by environmental factors and biological states, acting as confounders in genetic analyses. For instance, the levels of serum markers related to iron status are known to fluctuate based on the time of day blood samples are collected and an individual's menopausal status. [3] Although some studies meticulously controlled for such variables by standardizing blood collection times or restricting participant demographics, others included more heterogeneous populations with varied collection schedules and menopausal states, potentially introducing confounding effects that could obscure or falsely inflate genetic associations. [3] Additionally, the choice of tissue for gene expression experiments, such as unstimulated cultured lymphocytes, may not always accurately reflect protein levels in relevant tissues in vivo, particularly for inflammatory mediators like cytokines, which are highly responsive to cellular stimulation. [4]
Generalizability and Unexplained Genetic Variation
The generalizability of genetic association findings is often limited by the demographic characteristics of the study populations. Many genetic studies are conducted within cohorts primarily composed of individuals of white European ancestry or from genetically homogeneous founder populations. [4] While these populations offer advantages for initial discovery by reducing genetic heterogeneity, the observed genetic associations may not be directly transferable or have the same effect sizes in more diverse ethnic groups, which possess different genetic backgrounds and are exposed to unique environmental influences. Therefore, robust replication in ethnically varied cohorts is essential to establish the broader applicability and clinical utility of identified genetic variants.
Despite significant advances in identifying genetic associations, a substantial proportion of the heritability for many complex traits remains unexplained, a phenomenon often referred to as "missing heritability." This gap suggests that many contributing genetic factors, such as numerous variants with individually small effects, rare variants not adequately captured by current genotyping platforms, or complex interactions between genes and environmental factors, may still be undiscovered. [1] Furthermore, even for established genetic associations, the precise molecular and biological mechanisms linking a genetic variant to a phenotypic outcome are often not fully elucidated. For example, the detailed pathway explaining the strong association between ABO blood group and serum TNF-alpha levels remains an active area of research, highlighting the ongoing need for functional studies to translate genetic findings into mechanistic understanding. [4]
Variants
The tumor necrosis factor receptor superfamily member 10b, TNFRSF10B, also known as DR5, is a crucial death receptor involved in initiating programmed cell death (apoptosis) when it binds to its ligand, TRAIL. This process is vital for immune surveillance and suppressing tumor growth. Variants within TNFRSF10B, such as rs35974498, rs79042829, and rs7834266, may influence the receptor's expression levels, its ability to bind TRAIL, or the efficiency of its downstream signaling pathways, thereby modulating a cell's susceptibility to TRAIL-induced apoptosis. Complementary to TNFRSF10B are its paralogs, TNFRSF10D (DcR2) and TNFRSF10C (DcR1), which act as decoy receptors. These decoy receptors also bind TRAIL but lack the intracellular domains necessary to trigger cell death, effectively competing with TNFRSF10B and TNFRSF10A to inhibit apoptosis. [4] A variant like rs200239385 in TNFRSF10D or rs74480765 in TNFRSF10C could alter the production or function of these decoy receptors, shifting the delicate balance of TRAIL-mediated cell fate. Furthermore, the long non-coding RNA TNFRSF10B-AS1, an antisense transcript that spans into TNFRSF10C, can regulate the expression of these genes. Its variant rs111948087 might affect the stability or transcription of TNFRSF10B or TNFRSF10C mRNA, thus indirectly impacting the overall TRAIL signaling pathway and the cell's response to inflammatory signals. [5]
Several other genetic variants influence immune and inflammatory responses, which are closely linked to TNFRSF10B's role in cell death and immune regulation. For instance, the SH2B3 gene encodes an adaptor protein involved in cytokine signaling and the development of immune cells. The variant rs3184504, located in a region encompassing both ATXN2 and SH2B3, might affect SH2B3 function, potentially altering the cellular response to inflammatory cues and indirectly impacting TNF receptor family pathways. Similarly, CFH (Complement Factor H) is a critical regulator of the complement system, a part of the innate immune response essential for managing inflammation. A variant such as rs61229706 in CFH could compromise its regulatory capacity, leading to uncontrolled complement activation and chronic inflammation, which can profoundly influence cellular stress and the apoptotic threshold governed by TNFRSF10B. [4] In addition, the COLEC11 gene (Collectin-11) plays a role in innate immunity by recognizing specific molecular patterns associated with pathogens. Variants like rs13402561 and rs6542680, found within the RPS7 - COLEC11 locus, may influence immune recognition and subsequent inflammatory cascades, thereby modulating the cellular environment and potentially affecting how cells respond to death signals from receptors like TNFRSF10B. [5]
Other genes and their variants contribute to diverse cellular processes that can intersect with TNFRSF10B's functions. RHOBTB2, a member of the Rho GTPase family, regulates cell morphology, migration, and proliferation, often acting as a tumor suppressor. Variants such as rs150081341, rs41308108, and rs112470765 in RHOBTB2 could alter these cellular behaviors, potentially influencing cell cycle control or sensitivity to apoptotic signals, including those mediated by TNFRSF10B. PEBP4 (Phosphatidylethanolamine Binding Protein 4) is known for its role as a serine protease inhibitor and its involvement in cell growth, differentiation, and apoptosis. Variants like rs775616963 and rs117416770 could impact PEBP4's activity or stability, thus affecting cell survival pathways and potentially interacting with TNFRSF10B-dependent apoptosis. The RPS7 gene, encoding Ribosomal Protein S7, is primarily involved in protein synthesis but also has moonlighting functions related to apoptosis. Variants like rs13402561 and rs6542680 within the RPS7 region might influence its expression or non-ribosomal roles, affecting cellular stress responses that can lead to programmed cell death. [4] Furthermore, ATXN2 (Ataxin-2) is implicated in RNA processing and stress granule formation. The variant rs3184504 in the ATXN2-SH2B3 locus could impact ATXN2 function, influencing cellular stress responses that affect cell viability and susceptibility to apoptosis. Lastly, LINC02068, a long intergenic non-coding RNA, plays various regulatory roles in gene expression and cell cycle control. The variant rs231995 in LINC02068 could alter its regulatory function, thereby affecting fundamental cellular processes like proliferation and programmed cell death, which are inherently linked to the activity of death receptors such as TNFRSF10B. [5]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs35974498 rs79042829 rs7834266 |
TNFRSF10B | tumor necrosis factor receptor superfamily member 10b measurement |
| rs200239385 | TNFRSF10D | tumor necrosis factor receptor superfamily member 10b measurement |
| rs150081341 rs41308108 rs112470765 |
RHOBTB2 | urate measurement, bone tissue density tumor necrosis factor receptor superfamily member 10b measurement |
| rs74480765 | TNFRSF10C | tumor necrosis factor receptor superfamily member 10b measurement |
| rs13402561 rs6542680 |
RPS7 - COLEC11 | interleukin-1 beta measurement peptidyl-prolyl cis-trans isomerase FKBP14 measurement isochorismatase domain-containing protein 1 measurement protein MENT measurement sterol-4-alpha-carboxylate 3-dehydrogenase, decarboxylating measurement |
| rs111948087 | TNFRSF10B-AS1 - TNFRSF10C | tumor necrosis factor receptor superfamily member 10b measurement |
| rs775616963 rs117416770 |
PEBP4 | tumor necrosis factor receptor superfamily member 10b measurement |
| rs3184504 | ATXN2, SH2B3 | beta-2 microglobulin measurement hemoglobin measurement lung carcinoma, estrogen-receptor negative breast cancer, ovarian endometrioid carcinoma, colorectal cancer, prostate carcinoma, ovarian serous carcinoma, breast carcinoma, ovarian carcinoma, squamous cell lung carcinoma, lung adenocarcinoma platelet crit coronary artery disease |
| rs231995 | LINC02068 | tumor necrosis factor receptor superfamily member 10b measurement |
| rs61229706 | CFH | glypican-2 measurement protein measurement E3 ubiquitin-protein ligase RNF13 measurement interleukin-7 measurement interleukin-22 receptor subunit alpha-2 measurement |
References
[1] Yang, Q., et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, p. S12.
[2] O'Donnell, C. J., et al. "Genome-wide association study for subclinical atherosclerosis in major arterial territories in the NHLBI's Framingham Heart Study." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, p. S11.
[3] Benyamin, B., et al. "Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels." American Journal of Human Genetics, vol. 84, no. 1, 2009, pp. 60-65.
[4] Melzer, D., et al. "A genome-wide association study identifies protein quantitative trait loci (pQTLs)." PLoS Genetics, vol. 4, no. 5, 2008, p. e1000072.
[5] Benjamin, E. J., et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Medical Genetics, vol. 8, no. Suppl 1, 2007, p. S10.